# Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

> **NCT04926831** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** capmatinib

## Key facts

- **NCT ID:** NCT04926831
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-10
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-03-13
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was terminated early due to recruitment challenges.
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04926831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04926831, "Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04926831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*